Clinical trial NCT04402723: Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML
Official title: A Dose-escalated Phase Ⅰ Trial to Assess the Tolerance and Pharmacokinetics of Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML Patient
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Acute Myeloid Leukemia (AML)
Lead sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Sponsor class: INDUSTRY
First posted: 2020-05-27
Enrollment: 8
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: This phase Ⅰ study of Donafenib, an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases, is to assess safety and pharmacokinetics in patients with Relapsed AML.

Detailed description: Donafenib is a multikinase inhibitor which is acting on various cellular pathways involved in the genesis of acute myeloid leukemia (AML). Donafenib is therefore a promising candidate for improvement of chemotherapy results in AML. This clinical trial evaluates the safety and pharmacokinetics of Donafenib combination with Cytarabine/Daunorubicin for AML in patients between 18 and 55 years of age.

Eligibility criteria: Inclusion Criteria:

* Patients with diagnosed AML (except APL) according to the FAB and WHO classification, including AML evolving from MDS or other hematologic diseases and AML after previous cytotoxic therapy or radiation (secondary AML) .
* Patients with diagnosed Relapsed AML according to Chinese Guidelines for the Diagnosis and Treatment of Acute Myeloid Leukemia.
* relapse after 6 months of an morphological remission.
* Age ≥ 18 and ≤ 55 years.
* BMI ≥ 18 and ≤27.
* Informed consent, personally signed and dated to participate in the study.
* ECOG performance status of 0-1.
* Life expectancy of at least 12 weeks.
* Total serum bilirubin ≤1.5×ULN.
* Serum aspartate transaminase (AST) and/or alanine transaminase (ALT) ≤ 2.5×ULN.
* Serum creatinine ≤1.5×ULN.
* glomerular filtration rate ≥60 mL/min, as calculated with the Cockcroft-Gault formula.
* alkaline phosphatase ≤1.5×ULN.
* urine protein ≤1+, or Urine protein was quantified for 24h ≤0.5g.
* INR/PTT \<1.5×ULN.

Exclusion Criteria:

* Patients who are not eligible for standard chemotherapy as per discretion of the treating physician.
* Patients who have been treated with bone marrow transplantation.
* Central nervous system manifestation of AML.
* Cardiac disease: heart failure NYHA III or IV; unstable coronary artery disease (MI more than 6 months prior to study entry is permitted); serious cardiac ventricular arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted).
* Patients who have thrombosis events within 6 months prior to study entry is permitted.
* Pregnancy or breastfeed.
* Chronic pulmonary disease with relevant hypoxia.
* Patients undergoing dialysis.
* Known HIV and/or hepatitis C infection.
* Evidence or history of severe non-leukemia associated bleeding diathesis or coagulopathy.
* Evidence or recent history of CNS disease, including primary or metastatic brain tumors, seizure disorders.
* Blood pressure (BP) higher than systolic 140 mmHg and/or diastolic 90 mmHg after best treatment.
* Any severe concomitant condition which makes it undesirable for the patient to participate in the study or which could jeopardize compliance of the protocol.
* Patients with major surgery, open biopsy or significant traumatic injury within 4 weeks prior to study entry is permitted.
* Serious, non-healing wound, ulcer or bone fracture.
* Infection need antibiotic treatment.
* Cumulative therapeutic dose of Daunorubicin more than 300mg/m2.
* Concurrent malignancies other than AML.
* History of organ allograft.
* Allergy to study medication or excipients in study medication.

Primary outcomes:
measure: Safety(including the type, severity and frequency of AE)
timeFrame: through study completion, an average of 2 months
Secondary outcomes:
Other outcomes:
Locations:
city: Tianjin
country: China
facility: Institute of Hematology and Blood Disease Hospital
state: Tianjin
Study officials:
affiliation: Institute of Hematology and Blood Disease Hospital
name: Jianxiang Wang, Doctor
role: PRINCIPAL_INVESTIGATOR
References: